The Center for Biosimilars® recaps the top stories for the week of December 16, 2019.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 16, 2019.
Number 5 The United States is proceeding with a notice of proposed rulemaking to allow states to submit proposals for importing medicine from Canada.
Number 4: Ahead of Trazimera’s launch, researchers reported long-term safety and overall survival data for the Herceptin biosimilar in patients with HER2-positive metastatic breast cancer.
Number 3: The pan-Canadian Pharmaceutical Alliance engaged the Canadian Agency for Drugs and Technologies in Health to lead a multiphase stakeholder consultation process to encourage biosimilar uptake.
Number 2: Results of a phase 3 study Lupin’s etanercept biosimilar in patients with rheumatoid arthritis revealed that the biosimilar has lower immunogenicity than the reference drug.
Number 1: The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Pfizer’s biosimilar adalimumab referencing Humira.
Finally, last week, our e-newsletter asked whether you think a recent outcomes-based contract between Amgen and pharmacy benefit manager Abarca for Enbrel could help insulate the drug maker from eventual biosimilar competitors.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.